O	0	10	Randomized
O	11	17	window
O	18	20	of
O	21	32	opportunity
O	33	38	trial
O	39	49	evaluating
O	50	54	high
O	54	55	-
O	55	59	dose
B-intervention	60	67	vitamin
I-intervention	68	69	D
O	70	72	in
O	73	79	breast
O	80	86	cancer
O	87	95	patients
O	95	96	.

O	97	110	Epidemiologic
O	111	114	and
O	115	126	preclinical
O	127	131	data
O	132	139	suggest
O	140	141	a
O	142	151	potential
O	152	156	role
O	157	160	for
O	161	168	vitamin
O	169	170	D
O	171	173	in
O	174	180	breast
O	181	187	cancer
O	188	197	treatment
O	198	201	and
O	202	212	prevention
O	212	213	.

O	214	221	However
O	221	222	,
O	223	230	results
O	231	233	of
O	234	245	prospective
O	246	256	randomized
O	257	263	trials
O	264	267	are
O	268	280	inconsistent
O	280	281	.

O	282	285	The
O	286	295	objective
O	296	298	of
O	299	303	this
O	304	309	study
O	310	313	was
O	314	316	to
O	317	323	assess
O	324	327	the
O	328	335	effects
O	336	338	of
O	339	343	high
O	343	344	-
O	344	348	dose
O	349	364	cholecalciferol
O	365	366	(
O	366	373	vitamin
O	374	376	D3
O	376	377	)
O	378	380	on
O	381	387	breast
O	388	394	tumour
O	395	408	proliferation
O	409	412	and
O	413	422	apoptosis
O	422	423	.

O	424	426	We
O	427	436	conducted
O	437	438	a
O	439	450	prospective
O	450	451	,
O	452	462	randomized
O	462	463	,
O	464	469	phase
O	470	471	2
O	471	472	,
O	473	479	double
O	479	480	-
O	480	487	blinded
O	488	491	pre
O	491	492	-
O	492	500	surgical
O	501	507	window
O	508	510	of
O	511	522	opportunity
O	523	528	trial
O	528	529	.

B-eligibility	530	535	Newly
I-eligibility	536	545	diagnosed
I-eligibility	546	552	breast
I-eligibility	553	559	cancer
I-eligibility	560	568	patients
O	569	573	were
O	574	584	randomized
O	585	587	to
O	588	595	receive
O	596	598	40
O	598	599	,
O	599	602	000
O	603	605	IU
O	606	608	of
O	609	616	vitamin
O	617	619	D3
O	620	623	per
O	624	627	day
O	628	630	or
B-control	631	638	placebo
O	639	642	for
O	643	644	2
O	645	647	to
O	648	649	6
O	650	655	weeks
O	656	661	prior
O	662	664	to
O	665	671	breast
O	672	679	surgery
O	679	680	.

O	681	684	The
O	685	692	primary
O	693	700	outcome
O	701	704	was
O	705	708	the
B-outcome-Measure	709	717	relative
I-outcome-Measure	718	724	change
I-outcome-Measure	725	727	in
I-outcome-Measure	728	741	proliferation
I-outcome-Measure	742	743	(
I-outcome-Measure	743	747	Ki67
I-outcome-Measure	747	748	)
I-outcome-Measure	749	752	and
I-outcome-Measure	753	762	apoptosis
O	763	764	(
O	764	771	cleaved
O	772	779	caspase
O	780	781	3
O	782	791	apoptotic
O	792	797	assay
O	798	799	[
O	799	802	CC3
O	802	803	]
O	803	804	)
O	805	807	in
O	808	815	primary
O	816	822	breast
O	823	829	cancer
O	830	835	cells
O	836	839	pre
O	840	843	and
O	844	848	post
O	849	858	treatment
O	858	859	.

O	860	862	Of
B-total-participants	863	865	83
O	866	874	patients
O	875	885	randomized
O	885	886	,
B-total-participants	887	889	80
O	890	899	completed
O	900	903	the
O	904	909	study
O	910	911	(
B-intervention-participants	911	913	43
O	914	915	(
O	915	917	53
O	917	918	.
O	918	919	8
O	919	920	%
O	920	921	)
O	922	929	vitamin
O	930	931	D
O	932	935	and
B-control-participants	936	938	37
O	939	940	(
O	940	942	46
O	942	943	.
O	943	944	3
O	944	945	%
O	945	946	)
O	947	954	placebo
O	954	955	)
O	955	956	.

O	957	961	Mean
O	962	970	duration
O	971	973	of
O	974	978	drug
O	979	985	intake
O	986	989	was
O	990	992	19
O	993	997	days
O	998	999	(
O	999	1004	range
O	1005	1006	9
O	1006	1007	-
O	1007	1009	28
O	1010	1014	days
O	1014	1015	)
O	1015	1016	.

O	1017	1022	There
O	1023	1027	were
O	1028	1030	no
O	1031	1042	significant
O	1043	1054	differences
O	1055	1062	between
O	1063	1066	the
O	1067	1074	control
O	1075	1078	arm
O	1079	1082	and
O	1083	1086	the
O	1087	1094	vitamin
O	1095	1096	D
O	1097	1100	arm
O	1101	1103	in
B-outcome	1104	1111	percent
I-outcome	1112	1119	changes
I-outcome	1120	1122	of
I-outcome	1123	1129	either
I-outcome	1130	1134	Ki67
I-outcome	1135	1140	index
O	1141	1142	(
B-iv-cont-mean	1142	1143	1
I-iv-cont-mean	1143	1144	.
I-iv-cont-mean	1144	1145	6
I-iv-cont-mean	1145	1146	%
O	1147	1149	vs
O	1149	1150	.
B-cv-cont-mean	1151	1153	16
I-cv-cont-mean	1153	1154	.
I-cv-cont-mean	1154	1155	7
I-cv-cont-mean	1155	1156	%
O	1156	1157	,
O	1158	1159	p
O	1160	1161	=
O	1162	1163	0
O	1163	1164	.
O	1164	1166	25
O	1166	1167	)
O	1168	1170	or
B-outcome	1171	1174	CC3
O	1175	1176	(
B-iv-cont-mean	1176	1177	-
I-iv-cont-mean	1178	1180	55
I-iv-cont-mean	1180	1181	.
I-iv-cont-mean	1181	1182	9
I-iv-cont-mean	1182	1183	%
O	1184	1186	vs
O	1186	1187	.
O	1188	1189	-
B-cv-cont-mean	1190	1192	45
I-cv-cont-mean	1192	1193	.
I-cv-cont-mean	1193	1194	9
I-cv-cont-mean	1194	1195	%
O	1195	1196	,
O	1197	1198	p
O	1199	1200	=
O	1201	1202	0
O	1202	1203	.
O	1203	1205	28
O	1205	1206	)
O	1206	1207	.

B-outcome	1208	1213	Serum
I-outcome	1214	1216	25
I-outcome	1216	1217	-
I-outcome	1217	1231	hydroxyvitamin
I-outcome	1232	1233	D
I-outcome	1234	1235	(
I-outcome	1235	1237	25
I-outcome	1237	1238	-
I-outcome	1238	1241	OHD
I-outcome	1241	1242	)
I-outcome	1243	1249	levels
O	1250	1254	were
O	1255	1256	3
O	1257	1262	times
O	1263	1269	higher
O	1270	1272	in
O	1273	1276	the
O	1277	1284	vitamin
O	1285	1286	D
O	1287	1290	arm
O	1291	1292	(
B-iv-cont-mean	1292	1294	62
I-iv-cont-mean	1295	1299	nmol
I-iv-cont-mean	1299	1300	/
I-iv-cont-mean	1300	1301	L
O	1302	1304	vs
O	1304	1305	.
B-cv-cont-mean	1306	1309	246
I-cv-cont-mean	1310	1314	nmol
I-cv-cont-mean	1314	1315	/
I-cv-cont-mean	1315	1316	L
O	1316	1317	,
O	1318	1319	p
O	1320	1321	<
O	1322	1323	0
O	1323	1324	.
O	1324	1327	001
O	1327	1328	)
O	1328	1329	.

B-outcome	1330	1337	Adverse
I-outcome	1338	1345	effects
O	1346	1350	were
O	1351	1358	minimal
O	1359	1362	and
O	1363	1366	all
O	1367	1377	classified
O	1378	1380	as
O	1381	1386	grade
O	1387	1388	1
O	1388	1389	.

O	1390	1397	Despite
O	1398	1411	significantly
O	1412	1418	higher
O	1419	1425	levels
O	1426	1428	of
O	1429	1434	serum
O	1435	1437	25
O	1437	1438	-
O	1438	1441	OHD
O	1442	1444	in
O	1445	1448	the
O	1449	1456	vitamin
O	1457	1458	D
O	1458	1459	-
O	1459	1466	treated
O	1467	1472	group
O	1472	1473	,
O	1474	1478	this
O	1479	1482	was
O	1483	1486	not
O	1487	1497	associated
O	1498	1502	with
O	1503	1506	any
O	1507	1518	significant
O	1519	1526	effects
O	1527	1529	on
O	1530	1536	tumour
O	1537	1550	proliferation
O	1551	1553	or
O	1554	1563	apoptosis
O	1563	1564	.

O	1565	1570	These
O	1571	1579	findings
O	1580	1583	are
O	1584	1594	consistent
O	1595	1599	with
O	1600	1603	the
O	1604	1608	lack
O	1609	1611	of
O	1612	1619	benefit
O	1620	1628	observed
O	1629	1631	in
O	1632	1643	prospective
O	1644	1654	prevention
O	1655	1661	trials
O	1661	1662	.

O	1663	1668	Trial
O	1669	1681	registration
O	1682	1696	clinicaltrials
O	1696	1697	.
O	1697	1700	gov
O	1701	1712	NCT01948128
O	1712	1713	.
